MSH2 and cancer: While there is long‐standing evidence for the differences in tissue‐specific expressivity of cancer in patients with pathogenic MMR or HDR gene variants, MMR and HDR pathways are not mutually exclusive and the repair proteins involved interact physically in DNA damage signaling networks, for example, BRCA1 and MLH1 or BRIP1 and MSH2.34